University of Houston wraps up first cohort of program to turn innovators into entrepreneurs

fresh founders

Six members of the UH community participated in the inaugural Innov8 Hub's Innovators to Founders Cohort. Photo via UH.edu

A new accelerator at the University of Houston recently wrapped its first program for a cohort of five early-stage startups.

Known as the Innov8 Hub's Innovators to Founders Cohort, the accelerator is a founder-driven program in partnership with the UH Technology Bridge, the Innovation Center, and the Texas Gulf Coast Small Business Development Center (SBDC). Innov8 is designed to aid six to eight aspiring entrepreneurs bring their concepts to market and assist them in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

Founders recently showcased their work before potential partners and investors at the hub's first-ever Startup Pitch Day following the conclusion of the 12-week program.

“The goal of the programs is for the founders to launch new ventures and develop business plans they can use to raise money and attract C-suite level employees to join their team,” Tanu Chatterji, associate director of startup development at Tech Bridge and co-founder of Innov8 Hub, said in a statement. “These programs aren’t classroom-teacher driven so the founders have to commit to engage and spend the time necessary to reap the benefits.”

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program. Photo via UH.edu

The inaugural cohort included:

Shoujun Xu, UForce Biotechnology: Xu is a chemistry professor at UH and has developed a new technique of super-resolution force spectroscopy, or SURFS, and plans to launch his company, UForce Biotechnology, in the future. He aims to use the SURFS technique to advance drug screening. His pitch at the Startup Pitch Day was named the best of the night, and Xu went home with $7,500 in legal services and one year of coworking space free of charge.

Easy Anyama, ODX Health: Anyama is a fourth-year student in the UH College of Optometry. His company, ODX Health, aims to improve "data harmonization, interoperability and integration in eyecare to reduce inefficiencies and enhance health outcomes," according to UH.

Jeremy Tee and Easy Anyama, Ringit: Anyama joined fellow fourth-year student in the UH College of Optometry Jeremy Tee in a second pitch, Ringit. The startup aims to provide a low-cost medication management solution for the visually impaired. It is developing an adaptive labeling system that helps the visually impaired identify their medication and dosages independently via intuitive, "touch-based features," according to UH.

Jan Beetge, AltiSora: Beetge has developed "Botox for wood." The product is made from high- sustainability raw materials that are non-hazardous and non-toxic. Potential applications include waterproofing of electronic equipment or electrical cables or connections in cables, such as cables used in marine applications, according to the company's website.

Jason Shi, Smart Planter Project: Shi is developing a "high-tech planter, a device that autonomously takes care of your plants and keeps them healthy while you’re gone," according to UH. He aims to soon test the product with customers.

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program.

The Innov8 Hub also offers an SBIR/STTR Support Cohort and a WKI Program for Student Entrepreneurial Support Cohort.

Last year, UH also named eight graduate students to its first-ever UH-Chevron Energy Graduate Fellows cohort.
A new program launched by two UH-based organizations will help early-stage startups commercialize, apply for grants, and more. Photo via UH.edu

University of Houston launches new collaborative program for startups in Houston, Gulf Coast Region

ready to grow

Two University of Houston organizations have partnered up to further support early-stage startups in the Gulf Coast Region.

The university announced this month that its UH Technology Bridge and the UH Texas Gulf Coast Small Business Development Center are now accepting applications for a new, collaborative program that will help innovators and entrepreneurs develop a pitch or commercialization plan. The program will also guide participants in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants and other investments.

Applications are open to those with the university and across the region.

"We are excited to partner with the University of Houston Technology Bridge to provide this valuable support to early-tech startups in the Texas Gulf Coast region," Steven Lawrence, director of the UH Texas Gulf Coast SBDC Network, says in a statement. "Our program is designed to help innovators take their ideas to the next level and prepare for success in the marketplace."

"Our goal is to help innovators turn their ideas into successful businesses, and this partnership will help us achieve that goal," Tanu Chatterji, Associate Director of Startup Development at UH, echoes in the news release.

The UH Texas Gulf Coast SBDC Network is one of 14 SBDCs in the Texas Gulf Coast Region that's part of UH's C.T. Bauer College of Business and funded in part by the U.S. Small Business Administration. The centers provide no-cost and affordable business training and advising.

The UH Tech Bridge focuses on providing research and development space to UH-affiliated startups and entrepreneurs. The 15-building complex and its 31,000 square feet of incubator space houses more than 20 small companies and startups that provide internship and learning opportunities for UH students, along with several federally funded research centers and institutes.

Earlier this year, the Tech Bridge received a $2.875 million grant from the U.S. Department of Housing and Urban Development. The grant is slated to benefit the UH Industry & International Innovation Hub and will establish The Deck Innovation & Coworking Center.

Ramanan Krishnamoorti, the vice president of energy and innovation at the University of Houston who oversees the UH Technology Bridge, spoke with the Houston Innovators Podcast earlier this summer about UH's plans to build a central campus hub for innovation and the need to encourage more innovation and entrepreneurship.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings